ADC expert appointed as CEO

Until November 2025, Professor Pahl served as Chief Executive Officer of ADC-specialist Heidelberg Pharma AG, having previously held the position of Chief Scientific Officer. So he brings extensive expertise in the development and commercialization of ADCs to his new position. Before Heidelberg Pharma, Pahl held senior scientific leadership positions at Nycomed and Takeda Pharmaceuticals, where he led multidisciplinary drug development programs. Earlier in his career, he held academic roles at the Technical University of Berlin and the University of Erlangen-Nuremberg, where he was appointed Professor of Pharmacology and Toxicology and continues to teach, conducting internationally recognized research in molecular pharmacology and oncology.

Pahl joins Simris with the goal of maximizing the value of its differentiated ADC payload platform, broadening the Company’s capabilities and advancing multiple programs with the potential to accelerate Simris toward clinical development.

Professor Andreas Pahl, incoming Chief Executive Officer of Simris Biologics, commented his new position: “Simris has built a strong scientific foundation and developed a differentiated approach to ADC payload discovery. ADCs continue to reshape cancer treatment, and I believe the Company is well positioned to build on its progress and create significant value from its technology for the benefit of patients and its shareholders. I look forward to working with the team and bringing Simris to the next stage of development.”